Danish biotechnology company Genmab A/S (CPH:GMAB) on Monday reported data from the Phase 2 EPCORE DLBCL-3 and Phase 1b/2 EPCORE NHL-2 studies showing high response rates for epcoritamab-based treatments in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who were ineligible for standard chemotherapy regimens.

In the EPCORE DLBCL-3 trial, fixed-duration epcoritamab monotherapy achieved a 67% overall response rate and a 58% complete response rate among 66 patients, with durable responses, high minimal residual disease (MRD) negativity rates, and a median follow-up of 21.9 months.

In the EPCORE NHL-2 study, epcoritamab combined with standard of care rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone (R-mini-CHOP) delivered a 93% overall response rate and an 86% complete response rate in 28 patients, while demonstrating sustained MRD negativity and durable remissions after more than two years of follow-up.

Median duration of response, duration of complete response, progression-free survival, and overall survival were not reached in the combination study, with estimated two-year progression-free survival and overall survival rates of 76% and 82%, respectively.

Safety findings in both studies were consistent with previously reported profiles, with cytokine release syndrome, infections, neutropenia, anaemia, and other treatment-emergent adverse events observed.

The results were presented at the 2026 European Hematology Association Congress in Stockholm, and the full EPCORE DLBCL-3 findings were simultaneously published in The Lancet Haematology.